Biogen Inc. Overview
Pro stress-test →Biogen Inc is a well-established biopharmaceutical company that focuses on discovering, developing, manufacturing, and delivering therapies for neurological, rare, and autoimmune diseases. Once the undisputed titan of the Multiple Sclerosis (MS) market, the Cambridge-based biotechnology pioneer is now navigating an aggressive and complex transition. The company is undergoing a strategic pivot from legacy MS drugs to a growth portfolio anchored by Alzheimer's and rare disease therapies.
Strategic Profile
Pro stress-test →Biogen reported its fourth-quarter and full-year 2025 financial results on February 6, 2026, signaling a definitive shift from a legacy company plagued by patent cliffs to a leaner, growth-oriented neurology powerhouse. The company has successfully traded volume for value, with full year 2025 revenue at $9.9 billion and improved underlying profitability as the company shed high-cost, low-margin legacy programs. By diversifying into rare diseases and Alzheimer's, the company has stabilized its floor.
Competitive Landscape
Pro stress-test →In Alzheimer's, Biogen and Eisai are locked in a duopoly with Eli Lilly and its drug Kisunla, with market share split nearly 50/50 as of early 2026. Novartis and Sanofi continue to squeeze Biogen's legacy portfolio with oral generics and next-generation B-cell therapies. Roche is emerging as a significant threat with experimental drug trontinemab using "Brainshuttle" technology to clear amyloid plaques faster and with fewer side effects than Leqembi.
Industry Context
Biogen Inc. operates in Biopharmaceuticals / Neurology.
Key facts
Founded: 1978 · Headquarters: Cambridge, MA, US · Employees: 7,000+ · Revenue: $9.9B · Market cap: $27.2B